PerSimiO
Predicting Fracture Risk for Patients with Cancer and Osteoporosis
Company Overview
Snapshot
Founded in January 2015 by Prof. Zohar Yosibash, Dr. Nir Trabelsi, and Prof. MD Charles Milgrom, PerSimiO operates with 1–10 employees. The company has secured $955K in total capital across two funding rounds. PerSimiO's technology, a CT-based prediction model to simulate the response of human bones to load, was developed in 2015.
Business overview
PerSimiO is a health tech and life sciences company that develops superior prediction technology for assessing fracture risk in patients with cancer and osteoporosis. Its core technology is based on proprietary simulation of human bone response to load, validated through ex-vivo experiments using routine CT scans. The company offers a fully automated web-service, which can be integrated into hospital PACS or accessed as a locally hosted web-application, targeting the diagnosis and treatment of conditions like osteoporosis, metastatic tumors, and bone-weakening injuries. PerSimiO operates in the digital healthcare and medical decision support sectors, serving healthcare providers globally with products such as Simfini-TUMOR, Simfini-IMPLANT, Simfini-OSTEO, Simfini-DIABETES, and Simfini-SENIOR.
Log in to access full profile ›Company Intelligence Q&A
- What is PerSimiO's primary focus?
- PerSimiO focuses on predicting fracture risk for patients with cancer and osteoporosis using a proprietary simulation technology that models the response of human bones to load.
- When was PerSimiO founded?
- PerSimiO was founded in January 2015.
- Who are the founders of PerSimiO?
- PerSimiO was founded by Prof. Zohar Yosibash, Dr. Nir Trabelsi, and Prof. MD Charles Milgrom.
- What is the status of PerSimiO's products?
- PerSimiO's products are currently in the clinical trial stage.
- What is PerSimiO's total disclosed funding?
- PerSimiO has raised a total of $955K in disclosed funding across two non-equity rounds. This includes an undisclosed grant from the Office of the Chief Scientist in October 2015 and another undisclosed grant from the Israel Innovation Authority in August 2017.